Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
Hematologic Malignancies
About this trial
This is an interventional treatment trial for Hematologic Malignancies focused on measuring haploidentical transplantation, immunomagnetic cell sorting, allogeneic hematopoietic cell transplantation, dose reduced conditioning
Eligibility Criteria
Inclusion Criteria: Age <60, >18 years Karnofsky >60% High risk hematologic malignancy or relapse after preceding auto/allo HCT in patients with: ALL AML PNH MDS (RAEB-t/secondary AML) NHL ALL HD CML MM No HLA-identical MRD or URD if not preceding allo-HCT Use haploidentical donor with KIR-Mismatch if choice Exclusion Criteria: < 3 months after preceding HCT Active cerebral seizures > 30% blasts in BM if ALL/AML/CML-BC Completely chemo-refractory Preceding myocardial infarction Ejection fraction <30 % echocardiography Creatinine clearance <50 ml/min Respiratory insufficiency on supplemental O2 or DLCO < 30% Allergy against murine antibodies HIV infection Pregnancy Unable for informed consent
Sites / Locations
- University of Dresden Medical Center
- Center for Marrow Transplantation
- Medical Center University of Hamburg
- Medical Center University of Muenster
- South West German Cancer Center, University of Tuebingen Medical Center
- Deutsche Klinik für Diagnostik
- University of Wuerzburg Medical Center